Compare PAMT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAMT | LCTX |
|---|---|---|
| Founded | 1980 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 255.4M |
| IPO Year | 1995 | 1996 |
| Metric | PAMT | LCTX |
|---|---|---|
| Price | $11.87 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 12.3K | ★ 1.3M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,838,000.00 | $14,556,000.00 |
| Revenue This Year | $17.76 | $4.38 |
| Revenue Next Year | N/A | $10.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.15 | ★ 53.24 |
| 52 Week Low | $7.15 | $0.91 |
| 52 Week High | $17.75 | $2.09 |
| Indicator | PAMT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 39.85 |
| Support Level | $10.72 | $0.91 |
| Resistance Level | $13.04 | $1.18 |
| Average True Range (ATR) | 0.80 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.83 | 21.30 |
PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.